Home/Filings/4/0000950170-25-045295
4//SEC Filing

SCIASCIA THOMAS 4

Accession 0000950170-25-045295

CIK 0001563880other

Filed

Mar 25, 8:00 PM ET

Accepted

Mar 26, 4:30 PM ET

Size

8.3 KB

Accession

0000950170-25-045295

Insider Transaction Report

Form 4
Period: 2025-03-25
SCIASCIA THOMAS
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-25$1.43/sh+2,631$3,762224,004 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-03-252,6310 total
    Exercise: $1.43Exp: 2025-05-14Common Stock (2,631 underlying)
  • Sale

    Common Stock

    2025-03-25$6.60/sh2,631$17,365221,373 total
Footnotes (2)
  • [F1]Includes 1,058 shares purchased through the Issuer's employee stock purchase plan.
  • [F2]This option was granted on May 15, 2015. The 2,631 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.

Documents

1 file

Issuer

Trevi Therapeutics, Inc.

CIK 0001563880

Entity typeother

Related Parties

1
  • filerCIK 0001229946

Filing Metadata

Form type
4
Filed
Mar 25, 8:00 PM ET
Accepted
Mar 26, 4:30 PM ET
Size
8.3 KB